UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Human TRAV1-2-negative MR1-restricted T cells detect S. pyogenes and alternatives to MAIT riboflavin-based antigens

Nature communications, 2016-08, Vol.7 (1), p.12506-12506, Article 12506

2016

Volltextzugriff (PDF)

Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor

Nature medicine, 2008-12, Vol.14 (12), p.1390-1395

2008

Volltextzugriff (PDF)

Investigating and harnessing T-cell functions with engineered immune receptors and their ligands

Bruno Laugel

2015

Volltextzugriff (PDF)

Different T Cell Receptor Affinity Thresholds and CD8 Coreceptor Dependence Govern Cytotoxic T Lymphocyte Activation and Tetramer Binding Properties

The Journal of biological chemistry, 2007-08, Vol.282 (33), p.23799-23810

2007

Volltextzugriff (PDF)

The molecular determinants of CD8 co‐receptor function

Immunology, 2012-10, Vol.137 (2), p.139-148

2012

Volltextzugriff (PDF)

RcsCDB His‐Asp phosphorelay system negatively regulates the flhDC operon in Escherichia coli

Molecular microbiology, 2003-08, Vol.49 (3), p.823-832

2003

Volltextzugriff (PDF)

Interaction between the CD8 Coreceptor and Major Histocompatibility Complex Class I Stabilizes T Cell Receptor-Antigen Complexes at the Cell Surface

The Journal of biological chemistry, 2005-07, Vol.280 (30), p.27491-27501

2005

Volltextzugriff (PDF)

The multiple roles of the CD8 coreceptor in T cell biology: opportunities for the selective modulation of self-reactive cytotoxic T cells

Journal of leukocyte biology, 2011-12, Vol.90 (6), p.1089-1099

2011

Volltextzugriff (PDF)

Abstract LB220: S095029: a novel clinical-stage Fc-silenced NKG2A-blocking antibody with best-in-class potential

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.LB220-LB220

2023

Volltextzugriff (PDF)

Enhanced immunogenicity of CTL antigens through mutation of the CD8 binding MHC class I invariant region

European journal of immunology, 2007-05, Vol.37 (5), p.1323-1333

2007

Volltextzugriff (PDF)

Design of Soluble Recombinant T Cell Receptors for Antigen Targeting and T Cell Inhibition

The Journal of biological chemistry, 2005-01, Vol.280 (3), p.1882-1892

2005

Volltextzugriff (PDF)

The CD8 T Cell Coreceptor Exhibits Disproportionate Biological Activity at Extremely Low Binding Affinities

The Journal of biological chemistry, 2003-07, Vol.278 (27), p.24285-24293

2003

Volltextzugriff (PDF)

The HLA A0201–restricted hTERT540–548 peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor

Molecular cancer therapeutics, 2007-07, Vol.6 (7), p.2081-2091

2007

Volltextzugriff (PDF)

Adenosine and cAMP signalling skew human dendritic cell differentiation towards a tolerogenic phenotype with defective CD8+ T‐cell priming capacity

Immunology, 2013-04, Vol.138 (4), p.402-410

2013

Volltextzugriff (PDF)

Time to evolve: predicting engineered T cell-associated toxicity with next-generation models

Journal for immunotherapy of cancer, 2022-05, Vol.10 (5), p.e003486

2022

Volltextzugriff (PDF)

Enhancing Efficacy of TCR-engineered CD4 + T Cells Via Coexpression of CD8α

Journal of immunotherapy (1997), 2023-05, Vol.46 (4), p.132-144

2023

Volltextzugriff (PDF)

Bench, bedside, toolbox: T-cells deliver on every level

Frontiers in immunology, 2014, Vol.5, p.31-31

Laugel, Bruno

2014

Volltextzugriff (PDF)

Abstract 2281: DNA methyl transferase inhibitors (DNMTis) upregulate NY-ESO expression in several human primary cells: implications for co-therapy with engineered adoptive T-cell therapies

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2281-2281

2016

Volltextzugriff (PDF)

Engineering of Isogenic Cells Deficient for MR1 with a CRISPR/Cas9 Lentiviral System: Tools To Study Microbial Antigen Processing and Presentation to Human MR1-Restricted T Cells

The Journal of immunology (1950), 2016-08, Vol.197 (3), p.971-982

2016

Volltextzugriff (PDF)

Cladribine inhibits cytokine secretion by T cells independently of deoxycytidine kinase activity

Journal of neuroimmunology, 2011-12, Vol.240, p.52-57

2011

Volltextzugriff (PDF)

CD8 controls T cell cross-reactivity

The Journal of immunology (1950), 2010-10, Vol.185 (8), p.4625-4632

2010

Volltextzugriff (PDF)

Structural Mechanism Underpinning Cross-reactivity of a CD8+ T-cell Clone That Recognizes a Peptide Derived from Human Telomerase Reverse Transcriptase

The Journal of biological chemistry, 2017-01, Vol.292 (3), p.802-813

2017

Volltextzugriff (PDF)

Peptide mimic for influenza vaccination using nonnatural combinatorial chemistry

The Journal of clinical investigation, 2018-04, Vol.128 (4), p.1569-1580

2018

Volltextzugriff (PDF)

Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies

Frontiers in immunology, 2013-01, Vol.4, p.221-221

2013

Volltextzugriff (PDF)

Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside?

Journal for immunotherapy of cancer, 2022-05, Vol.10 (5), p.e003487

2022

Volltextzugriff (PDF)

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(51)

Publikationsform

Sprache

Englisch
(55)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Human TRAV1-2-negative MR1-restricted T cells detect S. pyogenes and alternatives to MAIT riboflavin-based antigens

Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor

Investigating and harnessing T-cell functions with engineered immune receptors and their ligands

Different T Cell Receptor Affinity Thresholds and CD8 Coreceptor Dependence Govern Cytotoxic T Lymphocyte Activation and Tetramer Binding Properties

The molecular determinants of CD8 co‐receptor function

RcsCDB His‐Asp phosphorelay system negatively regulates the flhDC operon in Escherichia coli

Interaction between the CD8 Coreceptor and Major Histocompatibility Complex Class I Stabilizes T Cell Receptor-Antigen Complexes at the Cell Surface

The multiple roles of the CD8 coreceptor in T cell biology: opportunities for the selective modulation of self-reactive cytotoxic T cells

Abstract LB220: S095029: a novel clinical-stage Fc-silenced NKG2A-blocking antibody with best-in-class potential

Enhanced immunogenicity of CTL antigens through mutation of the CD8 binding MHC class I invariant region

Design of Soluble Recombinant T Cell Receptors for Antigen Targeting and T Cell Inhibition

The CD8 T Cell Coreceptor Exhibits Disproportionate Biological Activity at Extremely Low Binding Affinities

The HLA A0201–restricted hTERT540–548 peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor

Adenosine and cAMP signalling skew human dendritic cell differentiation towards a tolerogenic phenotype with defective CD8+ T‐cell priming capacity

Time to evolve: predicting engineered T cell-associated toxicity with next-generation models

Enhancing Efficacy of TCR-engineered CD4 + T Cells Via Coexpression of CD8α

Bench, bedside, toolbox: T-cells deliver on every level

Abstract 2281: DNA methyl transferase inhibitors (DNMTis) upregulate NY-ESO expression in several human primary cells: implications for co-therapy with engineered adoptive T-cell therapies

Engineering of Isogenic Cells Deficient for MR1 with a CRISPR/Cas9 Lentiviral System: Tools To Study Microbial Antigen Processing and Presentation to Human MR1-Restricted T Cells

Cladribine inhibits cytokine secretion by T cells independently of deoxycytidine kinase activity

CD8 controls T cell cross-reactivity

Structural Mechanism Underpinning Cross-reactivity of a CD8+ T-cell Clone That Recognizes a Peptide Derived from Human Telomerase Reverse Transcriptase

Peptide mimic for influenza vaccination using nonnatural combinatorial chemistry

Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies

Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside?

Suchergebnisse filtern